Description
Cabozantinib belongs to targeted therapy drug used to cure medullary thyroid cancer and kidney cancer that has spread and It is label includes a black box warning of gastrointestinal perforations, fistulas, and hemorrhage.
Indication
Cabozantinib is used for the treatment of
Metastatic medullary thyroid cancer
Advanced renal cell carcinoma (RCC) who have to get before anti-angiogenic therapy.
Mechanism Of Action
Cabozantinib is a group of targeted therapy drug known as a tyrosine kinase inhibitor. It works by prohibiting the signals inner cancer cells which made them develop and divide. This may help to restrict or reduce the development of cancer. It can also prevent new blood vessels growing in cancer. Cancer cells necessary to make new blood vessels, so they can grow and spread.
Dosage and administration
Do not prescribe substitution for Cabozantinib tablets with Cabozantinib capsules.
The usual dose of Cabozantinib is 60 mg.
Administration Cabozantinib is without food.
Inform the patients not to eat for at least 2 hours before and 1 hour after taking Cabozantinib. Follow the treatment until the patient no longer experiences clinical benefit or experiences unacceptable toxicity.
Side Effects
• Hemorrhage
• GI perforations and fistulas
• Thrombotic events
• Hypertension and hypertensive crisis
• Diarrhea
• Palmar-plantar erythrodysesthesia
• Reversible posterior leukoencephalopathy syndrome.
Precautions
Monitor the patients for symptoms of perforations and fistulas contain abscess. stop Cabozantinib in patients who experience a perforation or a fistula.
Do not administer Cabozantinib to patients with a present history of hemorrhage or hemoptysis.
Discontinue the Cabozantinib in patients who develop an acute myocardial infarction, cerebral infarction, or any other clinically significant arterial thromboembolic complication.
Discontinue the Cabozantinib for the patient if have severe hypertension that cannot be controlled with anti-hypertensive therapy.
Drug Interaction
While combination with strong CYP3A4 inhibitor will increase the single dose plasma Cabozantinib exposure by 38%.
While combination with strong CYP3A4 inducers will decrease the single dose plasma Cabozantinib exposure by 77%
Concomitant use with MRP2 inhibitors may increase the exposure to Cabozantinib
Contraindication
Cabozantinib is contraindicated patients having a hypersensitivity reaction to the active substance or its excipients.
Pregnancy
Based on studies of animal and mechanism of action, Cabozantinib will cause fetal harm when given to pregnant women.
Advice the female not to become pregnant while on treatment with Cabozantinib.
Lactation
During treatment with Cabozantinib, advise the women not to breastfeed to infants
Storage
Store the drug at 20°C to 25°C
Keep away from the children resistances
Missed Dose
If the patient vomits after taking a dose of Cabozantinib or missed to take a dose, they should not take an extra dose, but to take the next dose at the regular time, skip the missed dose. Do not take the missed dose within 12 hours of next dose.
FOR MORE INFORMATION:
EMAIL:
PHONE:
91- 9987711567
No comments:
Post a Comment